Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of...
9 insider purchases on record · latest filing 2026-05-13.
Insiders have also filed 3 sale transactions at ODTX.